Advertisement

Using Receptor Antagonists in Binding Studies to Characterize a Mammalian Endothelin Receptor

  • J. Ruth Wu-Wong
Protocol
Part of the Methods in Molecular Biology™ book series (MIMB, volume 206)

Abstract

Endothelin (ET) is a peptide with 21-amino acid residues (1). Three distinct members of the ET family, namely, ET-1, ET-2 and ET-3, have been identified in humans through cloning (2). The effects of ETs on mammalian organs and cells are initiated by their binding to G-protein-linked receptors found in various tissues and cells (3). Two types of mammalian ET receptors, ETA and ETB, have been characterized, purified (4,5), and their cDNA have been cloned (6,7). ETA receptors are selective for ET-1 and ET-2, while ETB receptors bind ET-1, ET-2 and ET-3 with equal affinity. In addition, an ET receptor specific for ET-3 (termed ETc receptor or ETcR) was cloned from Xenopus laevis dermal melanophores (8). Although pharmacological studies suggest that there may be more endothelin receptor subtypes (9), no additional homologous mammalian cDNAs other than ETA and ETB have been identified.

Keywords

Binding Buffer Binding Study Scatchard Analysis Dissociation Rate Constant Antagonist Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi Y., Mitsui M., et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411–415.PubMedCrossRefGoogle Scholar
  2. 2.
    Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyachi T., Goto K., and Masaki T. (1989) The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA 86, 2863–2867.PubMedCrossRefGoogle Scholar
  3. 3.
    Sokolovsky M. (1992) Structure-function relationships of endothelins, sarafotoxins, and their receptor subtypes. J. Neurochem. 59, 809–821.PubMedCrossRefGoogle Scholar
  4. 4.
    Kozuka M., Ito T., Hirose S., Lodhi K. M., and Hagiwara H. (1991) Purification and characterization of bovine lung endothelin receptor. J. Biol. Chem. 266, 16,892–16,896.PubMedGoogle Scholar
  5. 5.
    Wada K., Tabuchi H., Ohba R., Satoh M., Tachibana Y., Akiyama N., et al. (1990) Purification of an endothelin receptor from human placenta. Biochem. Biophys. Res. Commun. 167, 251–257.PubMedCrossRefGoogle Scholar
  6. 6.
    Arai H., Hori S., Aramori I., Ohkubo H., and Nakanishi S. (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348, 730–732.PubMedCrossRefGoogle Scholar
  7. 7.
    Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., and Masaki T. (1990) Cloning of a cDNA encoding a nonisopeptide selective subtype of the endothelin receptor. Nature 348, 732–735.PubMedCrossRefGoogle Scholar
  8. 8.
    Karne S., Jayawickreme C. K., and Lerner M. R. (1993) Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J. Biol. Chem. 268, 19,126–19,133.PubMedGoogle Scholar
  9. 9.
    Bax W. and Saxena P. (1994) The current endothelin receptor classification: time for reconsideration? Trends Pharmacol. Sci. 15, 379–386.PubMedCrossRefGoogle Scholar
  10. 10.
    Haynes W. G. and Webb D. J. (1994) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344, 952–854.CrossRefGoogle Scholar
  11. 11.
    Salamoussa A., Lau W. A., Pennefather J. N., and Ventura S. (2000) The contractile effects of endothelins on the smooth muscle of the rat prostate gland. Eur. J. Pharmacol. 403, 139–145.PubMedCrossRefGoogle Scholar
  12. 12.
    Wagner O. F., Vierhapper H., Gasic S., Nowotny P., and Waldhausl W. (1992) Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur. J. Clin. Invest. 22, 277–282.PubMedCrossRefGoogle Scholar
  13. 13.
    Benigni A. and Remuzzi G. (1995) Endothelin in the progressive renal disease of glomerulopathies. Miner Electrolyte Metab. 21, 283–291.PubMedGoogle Scholar
  14. 14.
    Wu-Wong J. R. (2002) Endothelins in cellular proliferation and apoptosis: biological roles and clinical application. Analytical Pharmacology, in press.Google Scholar
  15. 15.
    Wu-Wong J. R., Berg C. E., Wang J., Chiou W. J., and Fissel B. (1999) Endothelin stimulates glucose uptake and GLUT4 translocation via activation of endothelin ETA receptor in 3T3-L1 adipocytes. J. Biol. Chem. 274, 8103–8110.PubMedCrossRefGoogle Scholar
  16. 16.
    Wu-Wong J. R., Berg C. E., and Kramer D. (2000) Endothelin stimulates glucose uptake via activation of endothelin ETA receptor in neonatal rat cardiomyocytes, J. Cardiovasc. Pharmacol. 36, S179–S183.PubMedGoogle Scholar
  17. 17.
    Simonson M. S. (1993) Endothelins: Multifunctional renal peptides. Physiol. Rev. 73, 375–411.PubMedGoogle Scholar
  18. 18.
    Wu-Wong J. R. and Opgenorth T. J. (1998) Endothelin and isoproterenol counter-regulate cAMP and mitogen-activated protein kinases. J. Cardiovasc. Pharmacol. 31, S185–S191.PubMedCrossRefGoogle Scholar
  19. 19.
    Chiou W., Magnuson S. R., Dixon D. B., Sundy S., Opgenorth T. J., and Wu-Wong J. R. (1997) Dissociation characteristics of endothelin receptor agonists and antagonists in cloned human type-B endothelin receptor, Endothelium: J. Endothelial Cell Res. 5, 179–189.Google Scholar
  20. 20.
    Wu-Wong J. R., Chiou W., Naugles, Jr. K. E., and Opgenorth T. J. (1994) Endothelin receptor antagonists exhibit diminishing potency following incubation with agonist. Life Sci. 54, 1727–1734.PubMedCrossRefGoogle Scholar
  21. 21.
    Wu-Wong J. R., Chiou W., Magnuson S. R., and Opgenorth T. J. (1994) Endothelin receptor agonists and antagonists exhibit different dissociation characteristics. Biochim. Biophys. Acta 224, 288–294.CrossRefGoogle Scholar
  22. 22.
    Wu-Wong J. R., Chiou W., Magnuson S. R., and Opgenorth T. J. (1995) Endothelin receptor in human astrocytoma U373MG cells: binding, dissociation, receptor internalization. J. Pharm. Exp. Ther. 274, 499–507.Google Scholar
  23. 23.
    Wu-Wong J. R., Chiou W., Dixon D. B., and Opgenorth T. J. (1995) Dissociation characteristics of endothelin ETA receptor agonist and antagonists. J. Cardiovasc. Pharmacol. 26, S380–S384.PubMedGoogle Scholar
  24. 24.
    Wu-Wong J. R. (1998) “Sticky” conundrums in the endothelin system: Unique binding characteristics of receptor agonists and antagonists. In Endothelin Receptors and Signaling Mechanisms, (Pollock D., ed.), R. G. Landes Company Biomedical Publishers, pp. 23–40.Google Scholar
  25. 25.
    Waggoner W. G., Genova S. L. and Rash V. A. (1992) Kinetic analyses demonstrate that the equilibrium assumption does not apply to [125I]endothelin-1 binding data. Life Sci. 51, 1869–1876.PubMedCrossRefGoogle Scholar
  26. 26.
    Takasuka T., Horii I., Furuichi Y., and Watanabe T. (1991) Detection of an endothelin-1-binding protein complex by low temperature SDS-PAGE. Biochem. Biophys. Res. Commun. 176, 392–400.PubMedCrossRefGoogle Scholar
  27. 27.
    Keen M. and MacDermot J. (1993) Analysis of receptor by radioligand binding. In Receptor Autoradiography (Wharton J. and Polak J. M., eds.), Oxford University Press, pp. 22–55.Google Scholar
  28. 28.
    Sokolovsky M., Shraga-Levine Z., and Galron R. (1994) Ligand-specific stimulation/ inhibition of cAMP formation by a novel endothelin receptor subtype. Biochemistry 33, 11,417–11,419.PubMedCrossRefGoogle Scholar
  29. 29.
    Bkaily G., Wang S., Bui M., and Menard D. (1995) ET-1 stimulates Ca2+ currents in cardiac cells. J. Cardiovasc. Pharmacol. 26, S293–S296.PubMedGoogle Scholar
  30. 30.
    Ihara M., Yamanaka R., Ohwaki K., Ozaki S., Fukami T., Ishikawa K., et al. (1995) [3H]BQ-123, a highly specific and reversible radioligand for the endothelin ETA receptor subtype. Eur. J. Pharmacol. 274, 1–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Nambi P., Pullen M., Wu H.-L., Lee D., Saunders D., Heys R., et al. (1996) Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors. J. Pharm. Exp. Ther. 277, 1567–1571.Google Scholar
  32. 32.
    Peter M. G. and Davenport A. P. (1995) Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Br. J. Pharmacol. 114, 297–302.PubMedGoogle Scholar
  33. 33.
    Wu-Wong J. R., Chiou W., Hoffman D. J., Winn M., von Geldern T. W., and Opgenorth T. J. (1996) Endothelins and endothelin receptor antagonists: binding to plasma proteins. Life Sci. 58, 1839–1847.PubMedCrossRefGoogle Scholar
  34. 34.
    Williams Jr. D. L., Murphy K. L., Nolan N. A., O’Brien J. A., Pettibone D. J., Kivlighn S. D., et al. (1995) Pharmacology of L-754,142, a highly potent, orally active nonpeptidyl endothelin antagonist. J. Pharm. Exp. Ther. 275, 1518–1526.Google Scholar
  35. 35.
    Sogabe K., Nirei H., Shoubo M., Nomoto A., Ao S., Notsu Y., and Ono T. (1993) Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J. Pharm. Exp. Ther. 264, 1040–1046.Google Scholar
  36. 36.
    Webb M. L., Bird J. E., Liu E. C. K., Rose P. M., Serafino R., Stein P. D., and Moreland S. (1995) BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist. J. Pharm. Exp. Ther. 272, 1124–1134.Google Scholar
  37. 37.
    Reynolds E. E., Keiser J. A., Haleen S. J., Walker D. M., Olszewski B., Schroeder R. L., et al. (1995) Pharmacological Characterization of PD 156707, an orally active ETA receptor antagonist. J. Pharm. Exp. Ther. 273, 1410–1417.Google Scholar
  38. 38.
    Clozel M., Breu V., Gray G.A., Kalina B., Loffler B.M., Burri K., et al. (1994) Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharm. Exp. Ther. 270, 228–235.Google Scholar
  39. 39.
    Wu-Wong J. R., Chiou W., Huang Z.-J., Vidal M. J., and Opgenorth T. J. (1994) Endothelin receptor in human pericardium smooth muscle cells: antagonist potency differs on agonist-evoked responses, Am. J. Physiol. 267, C1185–C1195.PubMedGoogle Scholar
  40. 40.
    Nambi P., Pullen M., Kincaid J., Nuthulaganti P., Aiyar N., Brooks D. P., et al. (1997) Identification and characterization of a novel endothelin receptor that binds both ETA-and ETB-selective ligands. Mol. Pharmacol. 52, 582–589.PubMedGoogle Scholar
  41. 41.
    Douglas W. P., Hay D. W., Luttmann M. A., Pullen M. A., and Nambi P. (1998) Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype? J. Pharmacol. Exp. Ther. 284, 669–677.Google Scholar
  42. 42.
    Douglas S. A., Beck G. R., Jr., Elliott J. D., and Ohlstein E. H. (1995) Pharmacologicevidence for the presence of three functional endothelin receptor subtypes in rabbit saphenous vein. J. Cardiovasc. Pharmacol. 26, S163–S168.PubMedGoogle Scholar
  43. 43.
    Kobayashi S., Tang R., Wang B., Opgenorth T., Stein E., Shapiro E., and Lepor H. (1994) Localization of endothelin receptors in the human prostate. J. Urol. 151, 763–766.PubMedGoogle Scholar
  44. 44.
    Wu-Wong J. R. (1999) Endothelin receptor antagonists: past, present, and future. In Current Opinion in Cardiovascular, Pulmonarys and Renal Investigational Drugs (Ripka W. C. and Doherty A. M., eds.), Pharma Press, London, UK, 346–351.Google Scholar

Copyright information

© Humana Press Inc. 2002

Authors and Affiliations

  • J. Ruth Wu-Wong
    • 1
  1. 1.Abbott LaboratoriesSanta Clara

Personalised recommendations

Cite protocol

Buy options